Beruflich Dokumente
Kultur Dokumente
Farmacuticas
Universidade de So Paulo.
Orientadora:
Profa. Dra Valentina Porta
So Paulo
2013
da
SUMRIO
LISTA DE ABREVIATURAS __________________________________________ 1
LISTA DE FIGURAS _______________________________________________ 1
LISTA DE QUADROS E TABELAS ____________________________________ 1
RESUMO ________________________________________________________ 2
1. INTRODUO __________________________________________________ 4
2. OBJETIVO _____________________________________________________ 6
3. MATERIAL E MTODOS __________________________________________ 6
3.1. Estratgias de pesquisa ________________________________________ 7
3.2. Critrios de incluso __________________________________________ 7
3.3. Critrios de excluso __________________________________________ 8
3.4. Coleta e anlise dos dados _____________________________________ 8
3.5. Anlise estatstica ___________________________________________ 14
4. RESULTADOS _________________________________________________ 14
4.1 Levantamento bibliogrfico de artigos nacionais ____________________ 14
4.2 Levantamento bibliogrfico de artigos internacionais _________________ 15
4.3 Resultados estatsticos ________________________________________ 16
5. DISCUSSO __________________________________________________ 18
6. CONCLUSO__________________________________________________ 19
7. REFERNCIA _________________________________________________ 21
8. ANEXOS _____________________________________________________ 37
ANEXO I ______________________________________________________ 37
ANEXO II _____________________________________________________ 39
1
LISTA DE ABREVIATURAS
ICER
ICUR
MS
Ministrio da Fazendo
SUS
LISTA DE FIGURAS
Figura 1. Descrio da incluso e excluso das publicaes nacionais. _________ 15
Figura 2. Descrio da incluso e excluso das publicaes internacionais. _____ 16
2
RESUMO
SANTOS,
A.M.
Panorama
geral
da
qualidade
dos
estudos
farmacoeconmicos nacionais e internacionais segundo as Diretrizes
Metodolgicas de Avaliaes Econmicas em Sade de 2009 (MS). 2013.
Trabalho de Concluso de Curso de Farmcia-Bioqumica Faculdade de
Cincias Farmacuticas Universidade de So Paulo, So Paulo, 2013.
Palavras-chave:
Metodolgicas.
Farmacoeconmia,
Custo-efetividade,
Brasil,
Diretrizes
3
RESULTADOS: Aps os filtros serem aplicados na reviso da literatura, obtivemos
um total de 29 artigos nacionais e 152 artigos internacionais nos quais foi aplicado
o questionrio. Para ambos os grupos, nacionais e internacionais, foi calculado a
mdia, sendo 0,80 e 0,92, respectivamente, de um total de 1,00. Atravs de uma
anlise estatstica podemos observar que houve diferena entre essas mdias.
CONCLUSO: A qualidade dos estudos internacionais mostrou-se superior
qualidade dos estudos nacionais. Apesar disso, podemos considerar que os
estudos nacionais apresentaram nota mdia alta, indicando cumprimento da maior
parte dos critrios definidos pelas Diretrizes Metodolgicas de Avaliaes
Econmicas em Sade9, as quais definem os pontos considerados essenciais no
desenvolvimento de estudos de avaliao econmica.
4
1. INTRODUO
5
importncia, porque a carncia de recursos exige que sejam alcanados melhores
resultados atravs do uso mnimo de recursos.
2,5
6
auxiliar na racionalizao dos custos. "A avaliao , em especial, parte
fundamental no planejamento e na gesto do sistema de sade. Um sistema de
avaliao
efetivo
deve
reordenar
execuo
de
aes
servios,
3,7
7
duas ou mais intervenes na rea da sade, considerando-se os custos e
benefcios proporcionados.12
que
comparavam
equipamentos,
procedimentos
ou
9
Quadro 1. Critrios para avaliao da qualidade metodolgica
1 O objetivo do estudo foi apresentado de forma clara e bem definido?
2 A perspectiva da anlise foi declarada? (pblico, privado, sociedade, etc)
3 Foi realizado anlise de incerteza? (teste estatstico e/ou de sensibilidade)
4
Quando o horizonte temporal foi maior que um ano, a taxa de desconto foi
aplicada?
10
Para todos os estudos, utilizaram-se apenas as informaes obtidas na
publicao original. No entanto, em alguns casos em que os dados fornecidos no
foram suficientemente detalhados, as referncias do artigo foram consultadas para
que as informaes relevantes fossem extradas. Por exemplo, se os autores
citaram um segundo estudo como fonte para efetividade, esse foi consultado para
determinar se continha as informaes citadas.
O
sistema
sim/no,
recomendado
pelo
Centre
for
Reviews
and
10
11
12
13
14
Nota
0,07
0,14
0,21
0,29
0,36
0,43
0,50
0,57
0,64
0,71
0,79
0,86
0,93
1,00
recebeu nota mxima (1,00), portanto foi utilizado para que pudssemos
exemplificar todos os itens do nosso questionrio.
11
analysis,
data
and
utility
data)
were
constructed
using
nonparametric
bootstrapping. 186
Comentrio: Informa a realizao de anlise de incerteza por meio de mtodos
determinsticos e probabilsticos.
5. Quando o horizonte temporal foi maior que um ano, a taxa de desconto foi
aplicada?
12
All costs and benefits were discounted at 5% per year as recommended by
the guidelines of the Canadian Agency for Drugs and
Technologies in
Health.186
Comentrio: Foi aplicada taxa de desconto de 5% para cada ano.
atravs
de
dados
primrios,
ensaios
clnicos
ou
revises
sistemticas/metanlises)?
a prospective, randomized, open-label, blinded end point trial. 186
Comentrios: A efetividade foi obtida atravs de dados primrios (ensaio
clnico).
13
During each one-year cycle, patients could experience a nonfatal MI and
transition into the post-MI state, undergo a revascularization procedure (PCI
or CABG) and transition into the postrevascularization state, or die from any
cause. Patients in the post-MI and postrevascularization states could remain
in their respective health states or die. 186
Comentrio: Os desfechos apresentam-se apropriados com base nas
indicaes e usos teraputicos dos medicamentos.
10. A descrio da fonte para obteno dos valores dos custos foi adequada?
The cost per 40 mg or 80 mg atorvastatin pill used in the model was $2.236
and the cost per generic simvastatin 20 mg or 40 mg pill was $1.100, as listed
in the current Ontario Drug Benefit Formulary (17). Dispensing fees were not
included. 186
Comentrio: A descrio da fonte de obteno dos dados foi includa,
possibilitando reprodutibilidade, e garantindo obteno dos mesmos dados por
outros pesquisadores que utilizem os mtodos propostos no estudo.
11. As fontes utilizadas para obteno dos custos foram adequadas para os
propsitos do estudo (por exemplo, valores de mercado, perspectiva dos
pacientes ou usurios, perspectiva dos gestores, julgamento de profissionais
de sade, etc)?
Alm da informao j citada na Questo 10, temos outro trecho: Each type
of end point-related hospitalization was assigned a total cost of hospitalization
(including overhead) based on the Ontario Case Costing Initiative (OCCI). 186
Comentrio: Ambos os trechos descrevem a utilizao de preos obtidos em
bases de dados que representam a perspectiva da sociedade.
14
A aplicao do formulrio gerou uma nota para cada artigo. A partir dessas
notas, foram obtidos obtivemos os valores de mdia e desvio padro e os valores
mnimos e mximos. A diferena na mdia para publicaes nacionais e
internacionais foi avaliada atravs do teste Mann-Whitney. O software Minitab foi
utilizado para realizao dos clculos.
4. RESULTADOS
dos
artigos
foi
descartada
principalmente
devido
aos
critrios
15
Em resumo, dos 86 artigos cujo texto completo foi analisado, 28 foram
includos para serem avaliados de acordo com o formulrio desenvolvido (Quadro
1). As publicaes selecionadas so apresentadas no ANEXO I.
16
Nota
Critrios presentes
0,57
17, 18
0,64
0,71
10
0,79
11
18, 26
0,86
12
0,93
13
1,00
14
17
Tabela 2. Pontuao obtida pela aplicao do questionrio adaptado a cada um dos trabalhos do
grupo Internacional. Os artigos foram agrupados de acordo com a nota atribuda a cada um.
Artigos (Nmero da
referncia bibliogrfica)
Nota
Critrios presentes
166, 195
0,71
10
0,79
11
0,86
12
0,93
13
1,00
14
Internacional
Mdia
0,80
0,92
Desvio Padro
0,15
0,08
Nota Mnima
0,57
0,71
Nota Mxima
1,00
1,00
18
Mediana
Nacional
28
0,7857
Internacional
152
0,9187
Estimao pontual
-0,1429
Intervalo de Confiana
(95%)
(-0,1428;-0,0715)
1552,5
0,0001*
5. DISCUSSO
O nmero absoluto de publicaes no Brasil ainda pequeno quando
comparado s regies do Reino Unido, Canad e Austrlia onde a avaliao
econmica uma das principais ferramentas para tomada de deciso poltica na
rea da sade. Porm existe sempre a possibilidade de vis de publicao, ou
seja, os estudos com resultado negativo ou nulo podem no terem sido
publicados. Portanto, nossos resultados podem subestimar o verdadeiro nmero
de anlises econmicas da sade na literatura.
Quando comparamos as mdias de ambos os grupos, nacional e
internacional, 0,80 e 0,92 respectivamente, observamos que os estudos
internacionais tem uma quantidade de informao maior do que os estudos
nacionais e portanto uma qualidade melhor segundo nosso formulrio de critrios
e podemos confirmar essa diferena atravs do teste de Mann-Whitney no qual
19
consideramos ndice de confiabilidade de 95%, sendo assim a hiptese nula (que
as mdias eram iguais estatisticamente) foi negada (p=0,0001), portanto as
mdias apresentam diferena estatisticamente significante.
Porm ao avaliar o grupo nacional isoladamente de acordo com as
recomendaes apresentadas pelas Diretrizes Metodolgicas de Avaliaes
Econmicas em Sade9, observamos que a sua mdia (0,80) alta quando
comparada com a escala na qual est inserida (0,00 1,00), ou seja, apresenta
uma mdia de 11 critrios presentes no total de 14. Porm o desvio padro
tambm alto o que demonstra uma grande variao na qualidade dos estudos,
portanto mesmo com uma diretriz publicada ainda existem muitos pesquisadores
que no seguem o padro sugerido por essa.
A base para esta avaliao foram as Diretrizes Metodolgicas de
Avaliaes Econmicas em Sade9 explicitadas em um questionrio para coleta
de dados sobre presena ou ausncia de caractersticas consideradas importantes
para este tipo de estudo. Esta metodologia apresentou a limitao de que no foi
possvel validar os mtodos utilizados para calcular os custos em cada estudo,
bem como no foi analisada a influncia da fonte financiadora sobre o resultado
do estudo.
Alm disso, o formulrio foi aplicado por um nico avaliador, sendo que
todos os resultados esto sobre a perspectiva do conhecimento do avaliador,
podemos ter um vis de interpretao, portanto um pool de avaliadores seria mais
adequado para o atual estudo.
6. CONCLUSO
Sade9,
as
quais
definem
os pontos
considerados essenciais
no
20
Embora este resultado seja encorajador, os estudos ainda no esto
plenamente adequados s diretrizes que o Brasil possui e no podem ser
comparados a estudos de principais polos como Canada, Reino Unido e Austrlia.
O aumento da quantidade de estudos de avaliao econmica em sade deve ser
acompanhado de um aumento no rigor metodolgico do desenho do estudo,
construo do modelo, coleta de dados e outros aspectos.
Assim adequando nossos estudos as novas diretrizes podemos utilizar a
farmacoeconomia como um importante brao na tomada de deciso no nosso pas
e no apenas como um complemento de outros resultados.
21
7. REFERNCIA
1.
2.
3.
4.
MOTA, D.M.; SILVA, M.G.C.; SUDO, E.C.; ORTN, V. Uso racional de medicamentos:
uma abordagem econmica para tomada de decises. Cinc. Sade Coletiva, p. 589-601,
2008.
5.
6.
BRASIL. Ministrio da Sade. MAIS SADE, Direito de Todos, 2008-2011. Braslia, p. 58, 2007. Disponvel em: http://bvsms.saude.gov.br/bvs/publicacoes/07_1052_M.pdf.
Acesso: 22 de agosto de 2012.
7.
8.
ISPOR. Custo em sade, qualidade e desfechos: o livro de termos da ISPOR = Health care
cost, quality and outcomes: ISPOR book of terms / Traduo Fbio Amaral Di Fini. So
Paulo: Associao Brasileira de Farmacoeconomia e Pesquisa de Desfechos ISPOR
Brasil, 2009.
9.
10.
11.
12.
22
18, 2006.
13.
CHIOU, C.F. et al. Development and validation of a grading system for the quality of costeffectiveness studies. Med Care. Vol.41, n.1, p.3244, 2003.
14.
Centre for Reviews and Disseminations, University of York. Systematic reviews. CRDs
guidance for undertaking reviews in health care. York: Centre for Reviews and
Disseminations, University of York; 2008.
15.
16.
17.
18.
19.
20.
21.
22.
23.
24.
23
25.
26.
27.
LEE, B. Y. et al. The potential economic value of a hookworm vaccine. In: (Ed.). Vaccine.
Netherlands: A 2010 Elsevier Ltd, v.29, p.1201-10, 2011.
28.
29.
30.
31.
32.
33.
34.
35.
36.
SASSE, A. D.; SASSE, E. C. [Cost-effectiveness analysis of adjuvant anastrozol in postmenopausal women with breast cancer]. Rev Assoc Med Bras, v. 55, n. 5, p. 535-40, SepOct 2009.
37.
38.
VAN GRIENSVEN, J. et al. Combination therapy for visceral leishmaniasis. In: (Ed.).
24
Lancet Infect Dis. United States: 2010 Elsevier Ltd, v.10, p.184-94, 2010.
39.
40.
41.
42.
43.
ZAHDI, M. R.; JUNIOR, I. M.; MALUF, E. M. C. P. Hepatitis A: The costs and benefits of
the disease prevention by vaccine, Parana, Brazil. Brazilian Journal of Infectious
Diseases, v. 13, n. 4, p. 257-261, 2009.
44.
45.
46.
47.
48.
49.
ANDREWS, N. J.
et al. Impact and effectiveness of 23-valent pneumococcal
polysaccharide vaccine against invasive pneumococcal disease in the elderly in England
and Wales. Vaccine, v. 30, n. 48, p. 6802-6808, 2012.
50.
51.
25
52.
BARKUN, A. N. et al. A one-year economic evaluation of six alternative strategies for the
management of uninvestigated upper gastrointestinal symptoms in Canadian primary care.
Canadian Journal of Gastroenterology, v. 24, n. 8, p. 489-498, 2010.
53.
BEAUDET, A. et al. Cost-utility of exenatide once weekly compared with insulin glargine
in patients with type 2 diabetes in the UK. Journal of Medical Economics, v. 14, n. 3, p.
357-366, 2011.
54.
BELSEY, J. D. Choice of angiotensin receptor blocker in moderate hypertension. A UKbased costbenefit comparison of olmesartan- and candesartan-based regimens. Journal of
Medical Economics, v. 14, n. 5, p. 553-561, 2011b.
55.
56.
57.
58.
59.
60.
61.
62.
BOTTEMAN, M. et al. Cost-effectiveness of denosumab (D) versus zoledronic acid (Z) for
skeletal-related event (SRE) reduction in bone-metastatic prostate cancer (mPC) in the
United Kingdom. Journal of Clinical Oncology, v. 30, n. 15, 2012.
63.
64.
26
diclofenac in the treatment of osteoarthritis in the UK; an update to the NICE model using
data from the CONDOR trial. Journal of Medical Economics, v. 15, n. 3, p. 465-472,
2012.
65.
66.
67.
CHALMERS, J.; BRADFORD, D.; JONES, C. The effect of methamphetamine and heroin
price on polydrug use: A behavioural economics analysis in Sydney, Australia.
International Journal of Drug Policy, v. 21, n. 5, p. 381-389, 2010.
68.
69.
70.
71.
72.
CHENG, J. W.; VU, H. Dabigatran etexilate: an oral direct thrombin inhibitor for the
management of thromboembolic disorders. In: (Ed.). Clin Ther. United States: Inc, v.34,
p.766-87, 2012.
73.
74.
CHILCOTT, J.; LLOYD JONES, M.; WILKINSON, A. Docetaxel for the adjuvant
treatment of early node-positive breast cancer: a single technology appraisal. Health
Technol Assess, v. 13 Suppl 1, p. 7-13, Jun 2009.
75.
CHIU, Y. et al. Access to the next wave of biologic therapies (Abatacept and Tocilizumab)
for the treatment of rheumatoid arthritis in England and Wales Addressing treatment outside
the current NICE guidance. Clinical Rheumatology, v. 31, n. 6, p. 1005-1012, 2012.
76.
27
77.
78.
79.
80.
DAKIN, H. et al. Cost effectiveness of tenofovir disoproxil fumarate for the treatment of
chronic hepatitis b from a canadian public payer perspective. PharmacoEconomics, v. 29,
n. 12, p. 1075-1091, 2011.
81.
82.
83.
DELEA, T. E. et al. Cost-effectiveness of zoledronic acid vs clodronic acid for newlydiagnosed multiple myeloma from the United Kingdom healthcare system perspective.
Journal of Medical Economics, v. 15, n. 3, p. 454-464, 2012.
84.
85.
86.
87.
88.
89.
DRETZKE, J. et al. A systematic review and economic evaluation of the use of tumour
necrosis factor-alpha (TNF-alpha) inhibitors, adalimumab and infliximab, for Crohn's
28
disease. Health Technol Assess, v. 15, n. 6, p. 1-244, Feb 2011.
90.
DUNLOP, W. et al. Quality of life benefits and cost impact of prolonged release
oxycodone/naloxone versus prolonged release oxycodone in patients with moderate-tosevere non-malignant pain and opioid-induced constipation: A UK cost-utility analysis.
Journal of Medical Economics, v. 15, n. 3, p. 564-575, 2012.
91.
92.
93.
94.
95.
96.
97.
98.
99.
100.
101.
102.
29
evaluation. In: (Ed.). Drugs Aging. New Zealand, v.26, p.791-801, 2009.
103.
104.
105.
106.
107.
HOYLE, M. et al. Cost-effectiveness of dasatinib and nilotinib for imatinib-resistant or intolerant chronic phase chronic myeloid leukemia. Value in Health, v. 14, n. 8, p. 10571067, 2011.
108.
109.
110.
111.
JONES, J. et al. Adefovir dipivoxil and pegylated interferon alpha for the treatment of
chronic hepatitis B: an updated systematic review and economic evaluation. Health
Technol Assess, v. 13, n. 35, p. 1-172, iii, Jul 2009.
112.
KANSAL, A. R. et al. Dabigatran versus rivaroxaban for the prevention of stroke and
systemic embolism in atrial fibrillation in Canada: Comparative efficacy and costeffectiveness. Thrombosis and Haemostasis, v. 108, n. 4, p. 672-682, 2012.
113.
114.
115.
30
116.
KNERER, G.; ISMAILA, A.; PEARCE, D. Health and economic impact of PHiD-CV in
Canada and the UK: A Markov modelling exercise. Journal of Medical Economics, v. 15,
n. 1, p. 61-76, 2012.
117.
LAFUMA, A.
et al. Treatment persistence and cost-effectiveness of
latanoprost/latanoprost-timolol, bimatoprost/bimatoprost-timolol, and travoprost/travoprosttimolol in glaucoma: An analysis based on the United Kingdom general practitioner
research database. Clinical Ophthalmology, v. 5, n. 1, p. 361-367, 2011.
118.
119.
120.
LIU, Z. et al. The economic value of primary prophylaxis using pegfilgrastim compared
with filgrastim in patients with breast cancer in the UK. Applied Health Economics and
Health Policy, v. 7, n. 3, p. 193-205, 2009.
121.
122.
123.
124.
125.
126.
127.
128.
MATZA, L. S. et al. Health state preferences associated with subcutaneous injections and
intravenous infusions for treatment of bone metastases. Journal of Clinical Oncology, v.
31
30, n. 15, 2012.
129.
130.
131.
132.
133.
134.
135.
136.
O'REILLY, D. et al. Using the Cardiff Long Term Model to estimate the long-term costutility of adding Onglyza(trademark) (saxagliptin) versus a thiazolidinedione (TZD) in
patients with type 2 diabetes mellitus (T2DM) with insufficient glycemic control using
maximal doses of metformin monotherapy and after failure or contraindication to
sulfonylurea combination therapy. Journal of Population Therapeutics and Clinical
Pharmacology, v. 17, n. 1, p. e109, 2010.
137.
138.
PAN, F. et al. Cost utility analysis based on a head-to-head phase 3 trial comparing
ustekinumab and etanercept in patients with moderate-to-severe plaque psoriasis: A
Canadian perspective. Value in Health, v. 14, n. 5, p. 652-656, 2011.
139.
PAPAIOANNOU, D. et al. Rituximab for the first-line treatment of stage III-IV follicular
lymphoma (review of Technology Appraisal No. 110): a systematic review and economic
evaluation. Health Technol Assess, v. 16, n. 37, p. 1-253, iii-iv, 2012.
140.
32
141.
142.
PAVEY, T. et al. Dasatinib, nilotinib and standard-dose imatinib for the first-line treatment
of chronic myeloid leukaemia: systematic reviews and economic analyses. Health Technol
Assess, v. 16, n. 42, p. iii-iv, 1-277, 2012.
143.
144.
145.
PETTIGREW, M.; DEUSON, R.; GARCES, K. Comparative net cost impact of the
utilization of romiplostim and intravenous immunoglobulin for the treatment of patients
with immune thrombocytopenia in Quebec. Blood, v. 118, n. 21, 2011.
146.
147.
PICOT, J. et al. The clinical effectiveness and cost effectiveness of bortezomib and
thalidomide in combination regimens with an alkylating agent and a corticosteroid for the
first-line treatment of multiple myeloma: A systematic review and economic evaluation.
Health Technology Assessment, v. 15, n. 41, p. i-204, 2011.
148.
149.
150.
151.
152.
RAUTENBERG, T. A. et al. Evaluating the cost utility of racecadotril for the treatment of
acute watery diarrhea in children: The RAWD model. ClinicoEconomics and Outcomes
Research, v. 4, n. 1, p. 109-116, 2012.
153.
154.
33
medicated plaster compared with pregabalin for the treatment of postherpetic neuralgia in
the UK: A Markov model Analysis. Clinical Drug Investigation, v. 30, n. 2, p. 71-87,
2010.
155.
156.
RODGERS, M. et al. Etanercept, infliximab and adalimumab for the treatment of psoriatic
arthritis: a systematic review and economic evaluation. Health Technol Assess, v. 15, n.
10, p. i-xxi, 1-329, Feb 2011.
157.
158.
159.
160.
161.
162.
163.
164.
165.
166.
34
167.
168.
169.
170.
171.
172.
173.
174.
THORLUND, K. et al. Budget impact analysis of boceprevir and telaprevir for the
treatment of hepatitis C genotype 1 infection. ClinicoEconomics and Outcomes Research,
v. 4, n. 1, p. 349-359, 2012.
175.
176.
177.
TUNIS, S. L. et al. Cost-effectiveness of insulin detemir compared to NPH insulin for type
1 and type 2 diabetes mellitus in the Canadian payer setting: Modeling analysis. Current
Medical Research and Opinion, v. 25, n. 5, p. 1273-1284, 2009.
178.
35
179.
180.
181.
182.
183.
VERDIAN, L.; YI, Y. Cost-utility analysis of rufinamide versus topiramate and lamotrigine
for the treatment of children with Lennox-Gastaut Syndrome in the United Kingdom.
Seizure, v. 19, n. 1, p. 1-11, 2010.
184.
185.
186.
187.
188.
189.
190.
191.
36
unfractionated heparin for prophylaxis of venous thromboembolism in medicine patients-A
pharmacoeconomic analysis. Clinical and Applied Thrombosis/Hemostasis, v. 17, n. 5, p.
454-465, 2011.
192.
193.
WILSON, E. C. et al. Cost effectiveness of leukotriene receptor antagonists versus longacting beta-2 agonists as add-on therapy to inhaled corticosteroids for asthma: a pragmatic
trial. Pharmacoeconomics, v. 28, n. 7, p. 597-608, 2010.
194.
195.
WOODS, B. et al. Bendamustine versus chlorambucil for the first-line treatment of chronic
lymphocytic leukemia in England and Wales: A cost-utility analysis. Value in Health, v.
15, n. 5, p. 759-770, 2012.
8. ANEXOS
ANEXO I
Lista de publicaes nacionais que foram avaliados segundo nossos critrios de qualidade.
Ttulo
Referncia
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Continua
Continuao
Ttulo
Evaluation of the awareness, control and cost-effectiveness of hypertension treatment in a Brazilian
city: populational study.
Cost-effectiveness and budget impact of saxagliptine as additional therapy to metformin for the
treatment of diabetes mellitus type 2 in the Brazilian private health system.
Topical versus peribulbar anesthesia in non-penetrating deep sclerectomy. A cost-effectiveness
analysis.
Cost-effectiveness of fondaparinux in patients with acute coronary syndrome without ST-segment
elevation.
Cost-effectiveness of introducing the 10-valent pneumococcal conjugate vaccine into the universal
immunisation of infants in Brazil.
Referncia
31
32
33
34
35
36
37
38
39
40
41
42
Hepatitis A: The costs and benefits of the disease prevention by vaccine, Parana, Brazil
43
ANEXO II
Lista de publicaes internacionais que foram avaliados segundo nossos critrios de qualidade.
Ttulo
Cost effectiveness of the two-compound formulation calcipotriol and betamethasone dipropionate gel
in the treatment of scalp psoriasis in Scotland
Cost-effectiveness evaluation of voriconazole versus liposomal amphotericin B as empirical therapy
for febrile neutropenia in Australia
Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in
febrile neutropenia in Australia
Pharmacoeconomic analysis of voriconazole vs. caspofungin in the empirical antifungal therapy of
febrile neutropenia in Australia
Cost-effectiveness of adalimumab in moderately to severely active ulcerative colitis
Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive
pneumococcal disease in the elderly in England and Wales
Referncia
44
45
46
47
48
49
50
51
A one-year economic evaluation of six alternative strategies for the management of uninvestigated
upper gastrointestinal symptoms in Canadian primary care
Cost-utility of exenatide once weekly compared with insulin glargine in patients with type 2 diabetes in
the UK
Choice of angiotensin receptor blocker in moderate hypertension. A UK-based costbenefit
comparison of olmesartan- and candesartan-based regimens
Optimizing adherence in hypertension: A comparison of outcomes and costs using single tablet
regimens vs individual component regimens
Economic evaluation of duloxetine versus serotonin selective reuptake inhibitors and venlafaxine XR
in treating major depressive disorder in Scotland
52
53
54
55
56
An economic evaluation of docetaxel and paclitaxel regimens in metastatic breast cancer in the UK
57
58
Cost-utility of Intravenous Immunoglobulin (IVIG) compared with corticosteroids for the treatment of
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP) in Canada
59
Continua
Continuao
Ttulo
Canadian cost-utility analysis of intravenous immunoglobulin for acute childhood idiopathic
thrombocytopenic purpura
Referncia
60
The effectiveness and cost-effectiveness of donepezil, galantamine, rivastigmine and memantine for
the treatment of Alzheimer's disease (review of Technology Appraisal No. 111): a systematic review
61
62
63
64
65
66
67
68
69
70
Clinical and cost-effectiveness of epoprostenol, iloprost, bosentan, sitaxentan and sildenafil for
pulmonary arterial hypertension within their licensed indications: a systematic review and economic
71
evaluation
Dabigatran etexilate: an oral direct thrombin inhibitor for the management of thromboembolic
disorders
The clinical effectiveness and cost-effectiveness of primary stroke prevention in children with sickle
cell disease: a systematic review and economic evaluation.
72
73
Continua
Continuao
Ttulo
Docetaxel for the adjuvant treatment of early node-positive breast cancer: a single technology
appraisal
Access to the next wave of biologic therapies (Abatacept and Tocilizumab) for the treatment of
rheumatoid arthritis in England and Wales Addressing treatment outside the current NICE guidance
Referncia
74
75
76
77
Cost-effectiveness of highly purified omega-3 polyunsaturated fatty acid ethyl esters in the treatment
of chronic heart failure: Results of Markov modelling in a UK setting
UK Dermatology Clinical Trials Network's STOP GAP trial (a multicentre trial of prednisolone versus
ciclosporin for pyoderma gangrenosum): Protocol for a randomised controlled trial
Cost effectiveness of tenofovir disoproxil fumarate for the treatment of chronic hepatitis b from a
canadian public payer perspective
Cost-utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to
metformin monotherapy in Type 2 diabetes mellitus
Cost effectiveness of travoprost versus a fixed combination of latanoprost/timolol in patients with
ocular hypertension or glaucoma: Analysis based on the UK general practitioner research database
Cost-effectiveness of zoledronic acid vs clodronic acid for newly-diagnosed multiple myeloma from
the United Kingdom healthcare system perspective
Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who
have received prior therapy with trastuzumab
Cost-effectiveness of rivaroxaban versus enoxaparin for the prevention of postsurgical venous
thromboembolism in Canada
Cost-effectiveness of onabotulinumtoxinA for the treatment of wrist and hand disability due to upperlimb post-stroke spasticity in Scotland
Cost-effectiveness of apixaban against current standard of care (SoC) for stroke prevention in atrial
fibrillation patients
Nab-Paclitaxel weekly or every 3 weeks compared to standard docetaxel as first-line therapy in
patients with metastatic breast cancer: An economic analysis of a prospective randomized trial
78
79
80
81
82
83
84
85
86
87
88
Continua
Continuao
Ttulo
A systematic review and economic evaluation of the use of tumour necrosis factor-alpha (TNF-alfa)
inhibitors, adalimumab and infliximab, for Crohn's disease
Referncia
89
Quality of life benefits and cost impact of prolonged release oxycodone/naloxone versus prolonged
release oxycodone in patients with moderate-to-severe non-malignant pain and opioid-induced
90
91
92
93
94
95
96
97
98
99
100
101
102
103
Continua
Continuao
Ttulo
Referncia
persistence
and
cost-effectiveness
of
104
105
106
107
108
109
110
111
112
113
114
115
116
117
latanoprost/latanoprost-timolol,
118
Continua
Continuao
Ttulo
Cost effectiveness of venlafaxine compared with generic fluoxetine or generic amitriptyline in major
depressive disorder in the UK
Cost-effectiveness of erlotinib versus docetaxel for second-line treatment of advanced non-small-cell
lung cancer in the United Kingdom
The economic value of primary prophylaxis using pegfilgrastim compared with filgrastim in patients
with breast cancer in the UK
Economic evaluation of etanercept in the management of chronic plaque psoriasis
Cost-effectiveness of insulin aspart compared to human insulin in pregnant women with type 1
diabetes in the UK
Oral versus i.v. antibiotics for community-acquired pneumonia in children: A cost-minimisation
analysis
Referncia
119
120
121
122
123
124
125
126
Cost-effectiveness of prasugrel versus clopidogrel in patients with acute coronary syndromes and
planned percutaneous coronary intervention: results from the trial to assess improvement in
therapeutic outcomes by optimizing platelet inhibition with Prasugrel-Thrombolysis in Myocardial
127
Infarction TRI..
Cost-effectiveness of infant vaccination with RIX4414 (Rotarix) in the UK
Health state preferences associated with subcutaneous injections and intravenous infusions for
treatment of bone metastases
Cost-effectiveness of combination therapy with etravirine in treatment-experienced adults with HIV-1
infection
Cost-effectiveness of rivaroxaban in the prevention of venous thromboembolism: A Canadian analysis
using the Ontario Ministry of Health Perspective.
Comparison of the metabolic and economic consequences of long-term treatment of schizophrenia
using ziprasidone, olanzapine, quetiapine and risperidone in Canada: a cost-effectiveness analysis
Cost-effectiveness of aldosterone antagonists for the treatment of post-myocardial infarction heart
failure
128
129
130
131
132
133
Continua
Continuao
Ttulo
Referncia
the
Cardiff
Long
Term
Model
to
estimate
the
long-term
cost-utility
of
134
135
136
adding
137
138
139
140
141
142
143
144
145
146
147
Continua
Continuao
Ttulo
Referncia
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
Continua
Continuao
Ttulo
Cost-effectiveness of bivalirudin versus heparin plus glycoprotein IIb/IIIa inhibitor in the treatment of
acute ST-segment elevation myocardial infarction
Use of analogue insulin in patients with Type 2 diabetes: An unnecessary expense for the NHS
Cost-effectiveness analysis of micafungin versus caspofungin for treatment of systemic Candida
infections in the UK
Referncia
163
164
165
166
167
A systematic review and economic evaluation of cilostazol, naftidrofuryl oxalate, pentoxifylline and
inositol nicotinate for the treatment of intermittent claudication in people with peripheral arterial
168
disease
Cost-effectiveness of latanoprost and timolol maleate for the treatment of glaucoma in Scandinavia
and the United Kingdom, using a decision-analytic health economic model
Economic evaluation of posaconazole versus standard azole therapy as prophylaxis against invasive
fungal infections in patients with prolonged neutropenia in Canada
Cost-effectiveness of systemic therapies for metastatic pancreatic cancer
Cost-effectiveness analysis of intranasal live attenuated vaccine (LAIV) versus injectable inactivated
influenza vaccine (TIV) for Canadian children and adolescents
The cost-effectiveness of macrogol 3350 compared to lactulose in the treatment of adults suffering
from chronic constipation in the UK
Cost-effectiveness of using an extensively hydrolysed formula compared to an amino acid formula as
first-line treatment for cow milk allergy in the UK
Budget impact analysis of boceprevir and telaprevir for the treatment of hepatitis C genotype 1
infection
Cost effectiveness of deferasirox compared to desferrioxamine in the treatment of iron overload in
lower-risk, transfusion-dependent myelodysplastic syndrome patients
Pharmaco-economic analysis of direct medical costs of metastatic colorectal cancer therapy with
XELOX or modified FOLFOX-6 regimens: Implications for health-care utilization in Australia
169
170
171
172
173
174
175
176
177
Continua
Continuao
Ttulo
Referncia
Cost-effectiveness of insulin detemir compared to NPH insulin for type 1 and type 2 diabetes mellitus
in the Canadian payer setting: Modeling analysis
Cost effectiveness of insulin glargine plus oral antidiabetes drugs compared with premixed insulin
alone in patients with type 2 diabetes mellitus in Canada
The cost-effectiveness of a 13-valent pneumococcal conjugate vaccination for infants in England
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in dialysis patients:
a Canadian payer perspective.
Cost-effectiveness of lanthanum carbonate in the treatment of hyperphosphatemia in chronic kidney
disease before and during dialysis
Cost-utility analysis of rufinamide versus topiramate and lamotrigine for the treatment of children with
Lennox-Gastaut Syndrome in the United Kingdom
178
179
180
181
182
183
184
185
Economic evaluation of high-dose (80 mg/day) atorvastatin treatment compared with standard-dose
(20 mg/day to 40 mg/day) simvastatin treatment in Canada based on the Incremental Decrease in
186
187
188
Myocardial Infar..
HP-HMG versus rFSH in treatments combining fresh and frozen IVF cycles: Success rates and
economic evaluation
The cost-effectiveness of duloxetine in chronic low back pain: A Quebec societal perspective
Low-molecular-weight
heparin
versus
unfractionated
heparin
for
prophylaxis
of
189
190
venous
191
Continua
Continuao
Ttulo
Referncia
192
03/05/13
03/05/13
Valentina Porta
193
194
195